Compounded GLP-1 ban: What providers need to know [SPONSORED CONTENT FROM NEBRASKA MEDICINE] In a recent regulatory shift, the FDA has ended the allowance for compounding pharmacies to produce copycat versions of popular GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
S., Mitchell, S
Levothyroxine The treatment for hypothyroidism is, in most cases, a single medication: levothyroxine , most commonly known by the brand name Synthroid, though Levo-T and other formulations exist
Individual results vary based on factors like starting weight, adherence to the protocol, diet, and exercise habits
Furthermore, an external validation is needed to provide better insight into the models generalizability
Examples include self-assembling peptide systems for controlled release and implantable long-duration semaglutide devices [21, 10]